Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewMSOPPE
Discontinued Product
0804 has been discontinued.
View all Glutamate (Metabotropic) Group II Receptors products.
Description: Group II/group III mGlu antagonist. More selective for group II than group III
Chemical Name: (RS)-a-Methylserine-O-phosphate monophenyl ester
Biological Activity for MSOPPE
mGlu receptor antagonist, slightly more selective for group II vs group III mGlu receptors. On primary afferent terminals in neonatal rat spinal cord, shows 3-fold greater selectivity for the (1S,3S)-ACPD-sensitive presynaptic receptor over the L-AP4-sensitive mGlu receptor (apparent KD values are 73 μM and 221 μM respectively). Has no activity on postsynaptic mGlu receptors or ionotropic glutamate receptors on neonatal rat motoneurones.
Technical Data for MSOPPE
| M. Wt | 275.2 |
| Storage | Store at RT |
| CAS Number | 170984-70-0 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for MSOPPE
Certificate of Analysis is currently unavailable on-line.
Please contact Customer Service
Please contact Customer Service
References for MSOPPE
References are publications that support the biological activity of the product.
Thomas et al (1996) α-Methyl derivatives of serine-O-phosphate as novel, selective competitive metabotropic glutamate receptor antagonists. Neuropharmacology 35 637 PMID: 8887973
Jane et al (1996) Phosphono substituted amino acids as selective metabotropic glutamate receptor antagonists. Phosphorous, Sulphur and Silicon 109-110 313
Thomas et al (1995) Serine-O-phosphate derivatives as novel, potent and selective metabotropic glutamate receptor (mGluR) antagonists. Soc.Neurosci.Abstr. 21 P616
View Related Products by Target
View Related Products by Product Action
View all Glutamate (Metabotropic) Group II Receptor Antagonists
Keywords: MSOPPE, MSOPPE supplier, Glutamate, (Metabotropic), Group, II, Receptors, 0804, Tocris Bioscience
Citations for MSOPPE
Citations are publications that use Tocris products.
Currently there are no citations for MSOPPE.
Reviews for MSOPPE
There are currently no reviews for this product. Be the first to review MSOPPE and earn rewards!
Have you used MSOPPE?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.